1. Adami, S., Libanati, C., Boonen, S., Cummings, S.R., Ho, P.R., Wang, A., Siris, E., Lane, J., Group, F.F.-H.W., Adachi, J.D., Bhandari, M., de Gregorio, L., Gilchrist, N., Lyritis, G., Moller, G., et al. (2012) Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J. Bone Joint Surg. Am., 94, 2113-2119.
2. Bernhard, A., Milovanovic, P., Zimmermann, E.A., Hahn, M., Djonic, D., Krause, M., Breer, S., Puschel, K., Djuric, M., Amling, M. & Busse, B. (2013) Micro-morphological properties of osteons reveal changes in cortical bone stability during aging, osteoporosis, and bisphosphonate treatment in women. Osteoporos. Int., 24, 2671-2680.
3. Bone, H.G., Hosking, D., Devogelaer, J.P., Tucci, J.R., Emkey, R.D., Tonino, R.P., Rodriguez-Portales, J.A., Downs, R.W., Gupta, J., Santora, A.C., Liberman, U.A. & Alendronate Phase, I.I.I.O.T.S.G. (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med., 350, 1189-1199.
4. Edwards, B.J., Bunta, A.D., Lane, J., Odvina, C., Rao, D.S., Raisch, D.W., McKoy, J.M., Omar, I., Belknap, S.M., Garg, V., Hahr, A.J., Samaras, A.T., Fisher, M.J., West, D.P., Langman, C.B., et al. (2013) Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J. Bone Joint Surg. Am., 95, 297-307.
5. Egol, K.A., Park, J.H., Rosenberg, Z.S., Peck, V. & Tejwani, N.C. (2014) Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin. Orthop. Relat. Res., 472, 2728-2734.